GNCA Genocea Biosciences Inc.

2.68
+0.07  (+3%)
Previous Close 2.61
Open 2.6
Price To Book 1.86
Market Cap 70,081,167
Shares 26,149,689
Volume 58,142
Short Ratio
Av. Daily Volume 115,283
Stock charts supplied by TradingView

NewsSee all news

  1. Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference

    Additional positive GEN-009 clinical immunogenicity data driven by ATLAS™ to be presented at ESMO Company to present at the Cantor Fitzgerald 2019 Global Healthcare Conference CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE

  2. Genocea to Present at September Healthcare Conferences

    CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Announced September 25, 2017 that development will be ceased.
GEN-003
Genital herpes
Topline data did not meet endpoints - September 2015
GEN-004
Universal vaccine candidate against pneumococcus
Phase 1/2 data due mid-2020
GEN-009 vaccine
Various cancers

Latest News

  1. Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference

    Additional positive GEN-009 clinical immunogenicity data driven by ATLAS™ to be presented at ESMO Company to present at the Cantor Fitzgerald 2019 Global Healthcare Conference CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE

  2. Genocea to Present at September Healthcare Conferences

    CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and